Your browser doesn't support javascript.
loading
Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.
Hudson, Kevin; Hancox, Urs J; Trigwell, Cath; McEwen, Robert; Polanska, Urszula M; Nikolaou, Myria; Morentin Gutierrez, Pablo; Avivar-Valderas, Alvaro; Delpuech, Oona; Dudley, Phillippa; Hanson, Lyndsey; Ellston, Rebecca; Jones, Alys; Cumberbatch, Marie; Cosulich, Sabina C; Ward, Lara; Cruzalegui, Francisco; Green, Stephen.
Afiliação
  • Hudson K; AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom. kevin.hudson@astrazeneca.com.
  • Hancox UJ; AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom.
  • Trigwell C; AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom.
  • McEwen R; AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom.
  • Polanska UM; AstraZeneca Pharmaceuticals, CRUK-CI Li Ka Shing Centre, Cambridge, United Kingdom.
  • Nikolaou M; AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom.
  • Morentin Gutierrez P; AstraZeneca Pharmaceuticals, CRUK-CI Li Ka Shing Centre, Cambridge, United Kingdom.
  • Avivar-Valderas A; AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom.
  • Delpuech O; AstraZeneca Pharmaceuticals, CRUK-CI Li Ka Shing Centre, Cambridge, United Kingdom.
  • Dudley P; AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom.
  • Hanson L; AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom.
  • Ellston R; AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom.
  • Jones A; AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom.
  • Cumberbatch M; AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom.
  • Cosulich SC; AstraZeneca Pharmaceuticals, CRUK-CI Li Ka Shing Centre, Cambridge, United Kingdom.
  • Ward L; AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom.
  • Cruzalegui F; AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom.
  • Green S; AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom.
Mol Cancer Ther ; 15(5): 877-89, 2016 05.
Article em En | MEDLINE | ID: mdl-26839307
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxidiazóis / Piperidinas / Neoplasias da Mama / Inibidores de Fosfoinositídeo-3 Quinase / Antineoplásicos Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxidiazóis / Piperidinas / Neoplasias da Mama / Inibidores de Fosfoinositídeo-3 Quinase / Antineoplásicos Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article